Vision therapy, A startup company based in Seattle, is developing a presbyopia correction eye drops, Raised 20 million US dollarsThe new cash was received within six months after the company raised $36 million. Supporters of this round include LSP, Sage Partners, Johnson & Johnson Innovation, etc.
The company’s main asset, BRIMOCHOL, is a once-daily eye drop designed to treat Presbyopia, A vision condition caused by aging that may make tasks such as reading difficult. According to the company, it affects approximately 123 million adults in the United States. Existing treatments include glasses, contact lenses or surgery.
Visus was founded in 2019 and is led by the CEO Ben BergoHe previously co-founded Lumos Diagnostics and Seattle-based Nohla Therapeutics. He was recently the executive officer of Planet Innovation.